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Summary
Background: Scrub typhus is an important febrile disease in Southeast Asia and is caused by
Orientia tsutsugamushi. Fluoroquinolones have proved to be effective for scrub typhus in an
animal model. However, it is unclear whether they are also effective clinically.
Methods: We retrospectively reviewed the hospital-based medical records of patients diagnosed
to have scrub typhus by an indirect immunofluorescence antibody assay or PCR at a large referral
hospital in Taiwan for a 6-year period (2001—2007). To determine the efficacy of levofloxacin for
the treatment of scrub typhus, we divided the patients into a levofloxacin-treated group and a
tetracycline antibiotics-treated group.
Results: Out of 132 patients with scrub typhus, 71 initially received levofloxacin and 61 initially
received tetracycline antibiotics. There was no statistically significant difference in the effective
rate between the two groups (91.5% and 95.1% cured, respectively; p = 0.648). The time to
defervescence in the levofloxacin-treated group was longer than in the other group (49  41.1
and 24  19.6 hours, respectively; p = 0.001). In the patients with higher APACHE II scores, higher
mortality was found in the levofloxacin-treated group (44.4% and 0%; p = 0.033).
Conclusions: Levofloxacin is effective in patients with scrub typhus, but has a longer time to
defervescence compared with tetracycline antibiotics. When levofloxacin is used for severe scrub
typhus, higher mortality may be attributed to the longer time to defervescence.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Scrub typhus is an acute febrile disease caused by Orientia
tsutsugamushi, which is transmitted to humans by the bite of
a larval Leptotrombidium mite. The disease is endemic from
northern Japan and far eastern Russia southward to northern
Australia and westward to Pakistan and Afghanistan.1 Com-
mon symptoms are fever, chills, headache, and malaise.
Some cases have severe complications, such as acute respira-
tory distress syndrome (ARDS), meningoencephalitis, disse-
minated intravascular coagulation (DIC), and septic shock.2—5
Tetracycline antibiotics or chloramphenicol is the conven-
tional therapy for treatment. Macrolides have been reported
as an effective choice for the treatment of scrub typhus,
especially in children and pregnant women.6—9
Ciprofloxacin has been proved as effective as chloram-
phenicol for the treatment of O. tsutsugamushi in an animal
model.10 In some reports, fluoroquinolones have been found
to be clinically effective in the treatment of scrub
typhus.3,11 In our clinical practice, we have also found
levofloxacin to be effective for the treatment of scrub
typhus. However, its efficacy has not yet been evaluated
in a clinical study. Therefore, we conducted a retrospective
study to evaluate the efficacy of levofloxacin for the treat-
ment of scrub typhus.
Methods
This study was performed retrospectively at the Buddhist Tzu
Chi General Hospital (Taiwan, Republic of China), a 900-bed
tertiary care university hospital and referral center. Patients
diagnosed to have scrub typhus by serologic or molecular
methods were enrolled in this study. Their medical records
were reviewed and data including demographic character-
istics, medical history, medications, laboratory data, and
outcome were collected for analysis. Those patients with
positive serologic tests for other acute infections or positive
blood cultures were excluded.
‘Defervescence’ was defined as the resolution of fever.
Time to defervescence was defined as the duration between
the start of antibiotics and the resolution of fever. ‘Cure’ was
defined as the resolution of fever after the same antibiotics.
‘Failure’ was defined as persistent fever without any identifi-
able cause, which caused mortality or made physicians
change the antibiotics.
Serologic testing for O. tsutsugamushi was performed by
determining the presence of immunoglobulin M (IgM)- and
immunoglobulin G (IgG)-specific antibodies using an indirect
immunofluorescence assay.12 The O. tsutsugamushi antigens
(Gilliam, Karp, and Kato) used were cultured in L cells. The
titers of IgM and IgG were determined in acute- and con-
valescent-phase sera. IgM1:80 or IgG increased four-fold in
the convalescent phase was considered a positive result. In
the molecular method, the genomic DNA of O. tsutsugamushi
was extracted using the QIAamp Blood Mini Kit (QIAGEN,
Hilden, Germany). O. tsutsugamushi was identified by 56-
kDa gene nested PCR.13
SPSS 11.5 for Windows (SPSS Inc., Chicago, IL, USA) soft-
ware was used for the statistical analysis. Pearson’s Chi-
square or Fisher’s exact two-tailed test was used to examine
nominal data and the unpaired Student’s t-test was used forcontinuous data. All tests were two-sided and a p-value of
0.05 was considered significant. Time to defervescence was
compared by Kaplan—Meier survival methods and the possi-
ble confounding factors to prolong time to defervescence
were adjusted by Cox regression models.
Results
One hundred thirty-nine patients were diagnosed to have
scrub typhus without other evidence of acute infections from
August 2001 through July 2007. Of these, one patient
received minocycline and levofloxacin simultaneously, one
patient received macrolides, and five patients received mox-
ifloxacin. They were excluded from this study. A total of 132
patients were included in this analysis. Among these
patients, 62 were proved to have scrub typhus by the mole-
cular method, 35 by the serologic method, and 35 by both
methods. Of the 62 patients with scrub typhus proved only by
the molecular method, 57 also had serologic tests, but con-
valescent sera were not available. Of the 35 patients with
scrub typhus proved by the serologic method, 13 patients
only had serologic testing for IgG and the others had testing
for both IgG and IgM. Of the 22 patients for whom both
serologic tests were done, five only had positive tests for
IgM because of a lack of convalescent sera.
We divided these cases according to the initial antibiotics
prescribed. There were 71 cases in the levofloxacin-treated
group and 61 cases in the tetracycline antibiotics-treated
group. In the levofloxacin-treated group, two patients were
treated with levofloxacin after the results of laboratory
testing and the others were treated empirically. The dosage
of levofloxacin was 500 mg once daily in patients with normal
renal function. In patients with abnormal renal function, the
dosage of levofloxacin was adjusted according to their esti-
mated creatine clearance rate. In the tetracycline antibio-
tics-treated group, 25 patients used doxycycline, 34
minocycline, and two tetracycline. Of these, eight patients
were treated with tetracycline antibiotics after the results of
laboratory testing and the others were treated empirically.
The dose of tetracycline used was 500 mg per 6 hours, the
dose of doxycycline used was 100 mg per 12 hours, and the
dose of minocycline used was 100 mg per 12 hours. The
baseline characteristics of the two groups are listed in
Table 1; there was no statistically significant difference
between these two groups.
Both antibiotic regimens were highly effective for the
treatment of scrub typhus (Table 2). In the levofloxacin-
treated group, six patients did not respond to levofloxacin.
Of these, three patients were treated with doxycycline
instead of levofloxacin and two patients survived; four
patients died in the levofloxacin-treated group. In the tetra-
cycline antibiotics-treated group, three patients did not
respond to tetracycline antibiotics and were subsequently
treated with levofloxacin; they all responded to this. The
effective rate was more than 90% in both groups and there
was no statistically significant difference between the two
groups.
The patients who responded to the initial antibiotics were
included in the analysis of time to defervescence. In the
levofloxacin-treated group, 65 patients responded to the
initial treatment and the time to defervescence was
49  41.1 hours. In the tetracycline antibiotics-treated
Table 1 Demographic and clinical characteristics of patients who received levofloxacin or tetracycline antibiotics for the
treatment of scrub typhus
Characteristic Treatment group p-Value
Levofloxacin (N = 71) Tetracycline antibiotics (N = 61)
Demographic
Age, years 51  13.8 50  19.3 0.720
No. male/female 40/31 34/27 1.000
Duration of symptoms before admission, days 9  5.1 7  3.9 0.052
Clinical
Maximum body temperature, 8C 39  1.3 39  0.9 0.123
Eschar 31 (43.7) 36 (59.0) 0.113
Skin rash 13 (18.3) 13 (21.3) 0.831
APACHE II score, points 7.1  5.0 5.9  3.6 0.138
Laboratory
WBC count,  109/l 9.0  3.0 8.0  3.4 0.059
Hemoglobin level, g/dl 12.6  2.0 14.0  8.1 0.204
Platelet count,  109/l 158.3  75.4 157.6  84.8 0.963
Alanine aminotransferase level, U/l 135.3  203.8 103.6  90.3 0.449
Blood urea nitrogen level, mg/dl 19.3  19.9 15.4  9.2 0.140
Serum creatinine level, mg/dl 1.2  1.0 1.1  0.7 0.560
Results are mean  standard deviation or n (%) of patients. APACHE, acute physiology and chronic health evaluation; WBC, white blood cell.
Table 2 Outcomes of patients who received levofloxacin or tetracycline antibiotics for the treatment of scrub typhus
Outcome Treatment group p-Value
Levofloxacin (N = 71) Tetracycline antibiotics (N = 61)
Cure 65 (91.5) 58 (95.1) 0.648
Death 4 (5.6) 0 (0)
Time to defervescence, hours 49  41.1a 24  19.6a 0.001
Results are n (%) of patients or median  standard deviation.
a The time to defervescence was measured in patients responding to initial antibiotics.
Figure 1 Kaplan—Meier curve of the time to defervescence in
patients initially treated with levofloxacin and tetracycline
antibiotics ( p = 0.0002).
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the time to defervescence was 24  19.6 hours. Kaplan—
Meier curves in association with a log-rank test on the time
to defervescence showed a statistically significant difference
between the groups ( p = 0.0002) (Figure 1). The time taken
to defervescence was longer in those patients treated with
levofloxacin. Acute physiology and chronic health evaluation
(APACHE) II score, acute renal failure, shock, Glasgow coma
scale, acute respiratory failure, and DIC were considered to
be possible confounding factors affecting the time to defer-
vescence. These were checked by Cox regression models
(Table 3). The choice of initial antibiotics and APACHE II
scores were the most important factors affecting the time
to defervescence.
We stratified the patients by APACHE II scores (Table 4).
The APACHE II score cut-off point was set by the sum of a
mean score and a standard deviation. In patients with lower
APACHE II scores (10), the two different initial antibiotics
had good efficacy for scrub typhus, however those patients
treated with levofloxacin took longer to defervescence
(47.7  42.2 and 23.5  19.4 hours; p = 0.001). In patients
with higher APACHE II scores (>10), lower efficacy and higher
mortality were observed in the levofloxacin-treated group.
There was a significant difference in mortality betweenthe two groups (44.4% and 0%; p = 0.033). The time taken
to defervescence was still longer in this group compared
with the tetracycline-treated group (62.4  23.1 and
27.1  22.0 hours; p = 0.015).
Table 3 Hazard ratios of all probable confounding factors for the time to defervescence by multivariate Cox regression models
Probable variables HR 95% CI p-Value
Initial antibiotics (levofloxacin vs. tetracycline antibiotics) 0.562 0.387—0.815 0.002
APACHE II score (points) 0.902 0.858—0.949 0.001
Shock 1.555 0.695—3.479 0.218
Duration of symptoms before admission, days 0.991 0.950—1.034 0.872
Acute renal failure 1.021 0.536—1.946 0.723
Glasgow coma scale, points 0.947 0.811—1.106 0.371
Acute respiratory failure 1.073 0.394—2.921 0.476
Disseminated intravascular coagulation 0.993 0.627—1.572 0.923
HR, hazard ratio; CI, confidence interval; APACHE, acute physiology and chronic health evaluation.
Table 4 Outcomes of patients stratified by APACHE II score
APACHE II score (points) Outcome Treatment group p-Value
Levofloxacin
(N = 71)
Tetracycline antibiotics
(N = 61)
10 No. cured/total cases 60/62 49/51 1.000
No. died/total cases 0/62 0/51
Time to defervescence, median hours  SD 47.7  42.2a 23.5  19.4a 0.001
>10 No. cured/total cases 5/9 9/10 0.141
No. died/total cases 4/9 0/10 0.033
Time to defervescence, median hours  SD 62.4  23.1a 27.1  22.0a 0.015
APACHE, acute physiology and chronic health evaluation; SD, standard deviation.
a The time to defervescence was measured in patients responding to initial antibiotics.
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Scrub typhus is an important febrile disease in Taiwan,
especially in eastern Taiwan where our hospital is located.
The annual number of confirmed cases in Taiwan has
increased from 39 in 1990 to 462 in 2005 due to improve-
ments in diagnostic facilities.4 Because of poor sensitivity
and specificity, the Weil—Felix test is no longer recom-
mended. In our study, most cases were confirmed by the
molecular method. The lack of a second serum specimen is
the reason why some cases were confirmed by the molecular
method but not by the serologic method. Convalescent
serum samples were not always collected because patients
were discharged after only a short duration of hospitaliza-
tion due to rapid defervescence, and they did not return for
further sampling.
Fluoroquinolones are active against a range of bacteria
and have improved pharmacokinetic properties within
cells.14,15 The in vitro activity of levofloxacin against obligate
intracellular organisms includingmany Rickettsia species was
proved by Maurin and Raoult.16O. tsutsugamushi is one of the
Rickettsia species, which are obligate intracellular organ-
isms. The activity of ciprofloxacin was found to be compar-
able to that of chloramphenicol in a murine model of scrub
typhus.10 Ciprofloxacin has also been shown to be effective in
several cases.3,11,17 The results of the present study reveal
that levofloxacin is as effective as tetracycline antibiotics for
the treatment of scrub typhus in patients with mild illness,
however the time to defervescence is longer. The prolonged
time to defervescence is similar to that found in Mediterra-
nean spotted fever treated with ciprofloxacin.18A case of scrub typhus transmitted by a needlestick injury
from a patient who was being given pefloxacin has been
reported.19 The illness of the index patient had deteriorated
under treatment with pefloxacin, but the prognosis was not
mentioned in the manuscript. The patient with scrub typhus
transmitted by the index patient was cured following treat-
ment with doxycycline. Long-term survival of O. tsutsuga-
mushi in people cured of symptomatic scrub typhus has been
recorded.20 Transmission may also occur in patients cured of
symptomatic scrub typhus. Co-infections of scrub typhus and
Leptospira species had been noted in several reports.21—23
Deterioration of the illness in the index patient may be
attributed to co-infection with other pathogens resistant
to pefloxacin.
In another report, three pregnant women with scrub
typhus had stillbirths under ciprofloxacin treatment.24 How-
ever, the efficacy of ciprofloxacin in the three womenwas not
mentioned. Untreated rickettisial infections are known to
cause transmission of scrub typhus frommother to fetus.9 Our
study showed that the patients treated with levofloxacin had
prolonged fever compared to those treated with tetracycline
antibiotics. Prolonged fever hints at its lower potency to
eradicate or inhibit intracellular O. tsutsugamushi, which
could be transmitted to the fetus and cause abortions.
Of the severe cases, four deaths occurred in the levoflox-
acin-treated group. These patients all died within three days
of admission and had presented with septic shock, acute
respiratory failure, change of consciousness, and DIC
(Table 5). Due to the symptoms mimicking sepsis caused by
Gram-negative bacteria, they were treated empirically with
levofloxacin. One of these patients was subsequently treated
Table 5 Data of the four patients who died in the levofloxacin-treated group
No. Age (years) Sex Duration of illness
before treatment (days)
Duration of
hospitalization (days)
APACHE II
score (points)
GCS score
(points)
Shock DIC ARDS ARF
1 66 M 15 3 21 12 + + + +
2 58 M 16 2 29 10 + + + +
3 47 M 12 1 15 13 + + + +
4 8 F ? 2 18 12 + + + 
APACHE, acute physiology and chronic health evaluation; GCS, Glasgow coma scale; DIC, disseminated intravascular coagulation; ARDS,
acute respiratory distress syndrome; ARF, acute renal failure.
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still died. In these severe cases, deterioration was rapid and
all died within three days. If levofloxacin takes longer to
eradicate or inhibit intracellular O. tsutsugamushi, pro-
longed production of cytokines can induce persistence of
DIC, causing multiple organ failure and death. In patients
with severe complications of scrub typhus, speed of action of
the antibiotics is of great importance. Previous reports have
shown a noteworthy proportion of scrub typhus patients with
probable co-infections with leptospirosis.21—23 In our study,
we did not perform serologic testing for leptospirosis in the
four treated with levofloxacin who died. Levofloxacin is not
effective in leptospirosis and multiple organ failure in the
four patients may have been due to co-infection of scrub
typhus and leptospirosis.
In the tetracycline antibiotics-treated group, three
patients without response to tetracycline antibiotics were
curedwith levofloxacin. The intensity of infection is different
with different strains of O. tsutsugamushi. Differences in
efficacy of antibiotics to the different strains has been
shown.25 Levofloxacin is not as good for patients with scrub
typhus, but could be considered as an alternative agent for
patients without response to tetracycline antibiotics. In
addition, levofloxacin is a broad-spectrum antibiotic and
may be more appropriate for mild febrile patients when it
is not possible to differentiate between scrub typhus and
bacterial sepsis.
Because of the retrospective design of this study, we did
not control all confounding variables that may have affected
survival and time to defervescence. The slow response to
treatment could have resulted from infection with particu-
larly virulent strains of O. tsutsugamushi.26,27 In this study,
we did not have data on the pathogen strains. In addition, we
did not control the timing of treatment and criteria for
selection of therapeutic regimens. Most patients were trea-
ted empirically with tetracycline antibiotics or levofloxacin.
Physicians may select tetracycline antibiotics for patients
with classic symptoms of scrub typhus. These factors may
influence the time to defervescence after treatment. How-
ever, this study adds more evidence for the clinical effec-
tiveness of levofloxacin in the treatment of scrub typhus.
Prospective studies involving large numbers of patients are
required to give more confirmed evidence of levofloxacin
efficacy in the treatment of scrub typhus.
In conclusion, our study adds more evidence for the
efficacy of levofloxacin in scrub typhus. However, it should
be noted that the defervescence period is longer in patients
treated with levofloxacin compared to those treated with
tetracycline antibiotics. Although the tetracycline antibio-tics remain the first-line antibiotic therapy for scrub typhus,
our study shows that levofloxacin may be an interesting
alternative to tetracycline antibiotics, especially in those
patients without response to tetracycline antibiotics.
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